Abstract: Compute-intensive packet processing (CIPP) in a computer system comprising a programmable computing platform is accelerated by using a packet I/O engine, implemented on the platform, to perform packet I/O functions, where the packet I/O engine is configured to achieve direct access to a network interface card (NIC) from a user application. For a Linux-based computer system, standard I/O mechanisms of Linux are bypassed and only the packet I/O engine is used in performing the I/O functions. Furthermore, the computer system is configured to: process a batch of packets, instead of packet by packet, in every function call; and when moving a packet between a buffer of an individual user application and a queue of the packet I/O engine, copy a packet descriptor of the packet instead the entire packet. In addition, workflows across different working threads are balanced and parallelism is exploited to fully utilize resources of the platform.

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-?C46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-? protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-?. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-?C46A mutants.

Abstract: A MAC protocol, useful for wireless local area networks (WLANs), is provided for improving throughput efficiency. The protocol includes three concurrent processes, and the channel is divided into a contention subchannel and a transmission subchannel. In the contention process, all nodes use the standard RTS/CTS mechanism operated on the contention channel to contend for a right of transmission. When one node gains the right, all the nodes store the contention result into their respective contention queue (CQ) buffers. In the transmission process, the nodes sequentially transmit their data over the transmission channel according to the order of the nodes stored in the CQ buffers. When one node finishes data transmission, the CQ buffers are updated. The contention process and the transmission process are connected by the queuing process, where each node dynamically updates its own CQ buffer according to the contention result and each instance of data transmission.

Abstract: A method for optimizing throughput of a network with stations adapted to transmit data to an access point includes the step of determining a respective required throughput for each station based on: respective time periods required for decreasing a count of a respective back-off counter associated with each of the stations, a transmission packet length of the respective station, and a probability of successful transmission for of the respective station. The respective required throughput so determined is a function of a respective transmission attempt rate for the station. The method further includes the step of determining the respective transmission attempt rate for each station for maximizing a sum of the respective required throughput such that a respective fixed throughput is provided for inelastic data flow in the network, a respective proportional throughput ratio is provided for elastic data flow in the network, and the throughput of the network is maximized.

Abstract: A computer system executes a method that detects an edge of an object with a Canny operator. The method calculates a gradient strength of pixels of the image and applies non-maximum suppression to the image to avoid spurious responses to edge detection. The image is divided into multiple partitions based on a brightness distribution of the pixels in the image and a set of dynamic threshold values. Multiple images for the partitions are superimposed to detect an edge of the object.

Abstract: A method for controlling an operation of a converter circuit adapted to regulate power transfer between a first voltage source and a second voltage source includes detecting a first voltage level of the first voltage source and a second voltage level of the second voltage source; calculating a power value based on the detected first voltage level and the detected second voltage level; comparing the calculated power value with a reference power value; and determining switching time of one or more switches in the converter circuit based on a compared result so as to regulate power transfer between the first voltage source and the second voltage source.

Abstract: A method for operating a follower vehicle in a vehicle platoon includes determining, during operation, whether the follower vehicle is operating in a normal state or an abnormal state based on an operation condition of a component of the follower vehicle, or a communication between the follower vehicle and a preceding vehicle in the vehicle platoon. The method further includes selecting a first control mode if the follower vehicle is in the normal state and a second control mode if the follower vehicle is in the abnormal state so as to control movement of the follower vehicle using the selected control mode. In the first control mode, the follower vehicle uses communication data received from the preceding vehicle in the vehicle platoon to control its movement. In the second control mode, the follower vehicle uses data obtained by one or more of its sensors to control its movement.

Abstract: A compound suitable for treating EGFR-dependent non-small cell lung cancer exceptionally inhibits activity of the EGFR kinase, in particular in EGFR-dependent non-small cell lung cancer with intrinsic or acquired resistance against at least one EGFR inhibitor. Methods for inhibiting EGFR kinase activity in non-small cell lung cancer cells which harbor an abnormality in the EGFR gene and for targeting cancer cells harboring an abnormality in EGFR gene by contacting EGFR-dependent non-small cell lung cancer cells with said compound are also provided. The compounds allow for an advantageous inhibition of the EGFR kinase activity and induction of apoptosis of the non-small cell lung cancer cells with abnormality in the EGFR gene. Hence, said compounds represent a highly promising treatment option for patients harboring EGFR-dependent cancer.

Abstract: A method of treating a subject, in particular a human, suffering from an autoimmune disease, preferably but not exclusively selected from systemic lupus erythematosus, multiple sclerosis or rheumatoid arthritis includes the step of administering an effective amount of a limonoid to the subject. The present invention further relates to methods of inhibiting the differentiation of T helper 17 cells, T helper 1 cells, T helper 2 cells and/or regulatory T cells and a method of screening substances for their inhibition of one or more of T helper 17 cell, T helper 1 cell, T helper 2 cell and/or regulatory T cell differentiation that may be used to treat an autoimmune disease. This invention provides highly advantageous and promising treatment options for autoimmune diseases, namely for attenuating inflammatory lymphocyte function.

Abstract: The present invention provides a method of power control for a plurality of secondary users (SUs), or unlicensed users, in a cognitive radio network having a plurality of primary users (PUs), or licensed users. The method comprises determining an optimal power level for each of the SUs such that a total throughput of all the SUs is maximized while satisfying an individual throughput requirement of each SU and an interference limit constraint of the PUs. In particular, a case having two SUs is considered.

Abstract: A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.

Abstract: One example embodiment relates to a method of treating non-small cell lung cancer by administering a compound of formula (I) to a patient.

Abstract: One embodiment relates to a method of treating lung cancer by administering a compound of formula I to a patient.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is tangeretin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

Abstract: A method improves an anti-eavesdropping (AE)-shelter that emits interference signals that protect communication between legitimate transmitters and legitimate receivers in the AE-shelter. The method includes determining a circular boundary for the AE-shelter; improving the AE-shelter by uniformly placing a number of jammers at the boundary; tuning emitting power of the jammers; and improving a coverage area of the interference signals.

Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

Abstract: A compound suitable for treating cancer, in particular NSCLC, inhibits activity of oncogenic ROS1 kinase and ALK kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety. The presence of the structural components allows for an advantageous interaction with the ROS1 kinase domain and, further, with the ALK kinase domain. Hence, said compound represents a highly promising opportunity for patients bearing ROS1- or ALK-dependent cancer. A composition, in particular a pharmaceutical composition, includes the compound. A method for targeting cancer cells harboring an abnormality in ROS1 gene or ALK gene includes contacting a cell with the compound.